Menu
Back to Journals » Drug Design, Development and Therapy » Volume 9
Targeting the hypoxia pathway to treat pancreatic cancer
Authors Erickson L, Highsmith Jr. E, Fei P, Zhang J
Received 14 January 2015
Accepted for publication 10 March 2015
Published 8 April 2015 Volume 2015:9 Pages 2029—2031
DOI https://doi.org/10.2147/DDDT.S80888
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Prof. Dr. Wei Duan
Lori A Erickson,1 W Edward Highsmith Jr,1 Peiwen Fei,2 Jun Zhang1
1Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA; 2University of Hawaii Cancer Center, University of Hawaii, Honolulu, HI, USA
Abstract: The correlation between hypoxia and pancreatic cancer has long been discussed. Hao’s research team made many efforts on revealing the oncogenic function of hypoxic inducible factor-1 (HIF-1) in pancreatic cancer progression and development in recent years. Based on their research, they linked micro-environmental regulation of pancreatic cancer and its clinical significance. Hao’s research team suggests it is a promising approach to target HIF-1 for the management of pancreatic cancer progression and invasion.
Keywords: hypoxia, HIF-1, pancreatic cancer
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.